We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.125 | 17.75 | 18.50 | 18.125 | 18.125 | 18.13 | 75,129 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.38 | 16.52M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/2/2017 16:35 | Just out of interest, when I read the main thread, most of the shareholders appear to be overweight and/or have high blood pressure or high cholesterol. Just a thought but if Opti did eventually come good would any of you still be alive to spend your ill gotten gains? ;) P.S. Out of interest I tried a Go-Figure shake. If it helps anybody, I didn't like the taste so I added a soup starter, steak and chips for main, a crème Brulee dessert and washed it down with a pint of Boddingtons. I think the shake must have worked because I went for at least two hours without feeling hungry again. In fact for supper I just had a shake and a cheese and pickle sandwich. Oh and a packet of crisps, and then some pork scratchings......... Actually that last paragraph isn't entirely true. It was two packets of crisps ;) | michaelmouse | |
09/2/2017 16:17 | riskybusiness1 - "maybe the mouse on the other thread will live to regret putting more time and effort in to writing rubbish than doing proper research." If you think I write rubbish then that's your prerogative. We clearly beg to differ. I have no issue with the company and indeed wish them well in their endeavours. However, the company is already valued in the multi-millions and has recorded at the half-year just £88,000 in revenues. Despite your so-called research the fact remains that the business model is not yet proven and meaningful revenues and profits are a considerable way off. Therein lies the considerable risk at the current valuation. There is no room for error and no margin of safety. If I'm wrong then I can live with that. IMV the risk/reward is massively skewed towards risk rather than reward. There are always plenty of opportunities out there with better odds imo. | michaelmouse | |
09/2/2017 16:05 | Well, haven't had to take advantage of the Go Figure range as not overweight, but I do have raised cholesterol and high blood pressure..... so as soon as I can get my hands on a pack of this stuff the better!! I would enjoy better health, less likely to have heart attack, and therefore live longer so as to enjoy the huge future dividends Im sure owning many thousands of Opti shares will produce!! Win , Win.! ( is that train of thought realistic? Hope so) | nicktopten | |
09/2/2017 15:53 | Good post risky. | someuwin | |
09/2/2017 15:41 | This is only one product in one platform. Interesting the presentation mentions that the next group to study will be the higher cholesterol group which had a 26% reduction. Replicate this with 100+ people and this product will be big whoever the partner. The latter part of the presentation showed the 3x extra increase in the cholesterol reduction when the lpgos from the optibiotic platform was added to the probiotic. Shows the value overlap between the platforms very clearly. Clear example of how opti can use this tech to improve probiotics health benefits - dsm £10bn+ mkt cap worlds biggest ingredient supplier using AND PAYING FOR (six figure sum) the privilege to use Optis tech to enhance their products whilst opti retains a future 7-15% license revenue and royalties. How many other companies with established sales will want to enhance their products in an market transitioning from general well bring to a focus on specific health benefits. Chr hannsens purchasing of Valios single strain for £60m shows the market leaders moving in for proven specific health benefits. This accumulation of data by opti is the start of such process. What happens if these next generation Synbiotics are used in clinicals within a high cholesterol test group (The probiotic alone showed a 26% reduction in this group). Taking in to account the lpgos has a 3x increase in the probiotics ability to reduce cholesterol..... maybe the mouse on the other thread will live to regret putting more time and effort in to writing rubbish than doing proper research.Time will tell. | riskybusiness1 | |
09/2/2017 15:09 | Here are the posters from Probiota: | parob | |
09/2/2017 14:13 | Yes, impressive results in the presentation. As the wider science based companies see what OPTI has, it is no wonder SOH has been so busy. Being on a number of different tablets already means I am reluctant to add more. However, a simple additive to food or similar supplement I would be very willing to consume. | rafboy | |
09/2/2017 13:49 | Another great presentation by SOH. Said he had a dozen people from a large range of companies waiting to speak to him afterwards who were "interested in distributing and marketing our products".Most of the reduction in total and bad cholesterol was within 6 weeks - so pretty fast results! | parob | |
09/2/2017 13:26 | Highly likely imo neft | someuwin | |
09/2/2017 13:05 | Thanks someuwin for posting the presentation link. He says and i can quite understand that it is a very costly business to involve actual human studies, a number of 49 taking part was mentioned. Partners to sponsor further human study testing. The results in lowering BAD cholesterol and blood pressure and increasing GOOD cholesterol are impressive. I just wonder if good old P & G have been funding their own human study testing all these months. | neftanikoff | |
09/2/2017 12:42 | SOH does a great job of explaining the presentation slides there. Has been submitted to the British Journal of Nutrition for peer review. All set for spring launch of cardiovascular products. But clearly talk of next generation pipeline suggests much more to come further down the line. | someuwin | |
09/2/2017 12:11 | Not much mileage there Somuwin, would you say? Nor in the bullish PSL write-up/tip. Bring on something meaty? | owenmo | |
09/2/2017 12:01 | PRESENTATION: Opibiotix Health Plc at ProBiota, Berlin Feb 2017 OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced in January that it has had two abstracts accepted for presentation at ProBiota 2017 in Berlin from 1-3 February 2017. ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiota focused food and pharma industries. The conference is world renowned as a key meeting place for a community of scientists and business leaders who want to translate science into new products in the growing supplements and ingredients market. CEO Stephen O’Hara talks through the presentation on LP-LDL®: Cholesterol & hypertension reduction – Next generation pre, pro, and synbiotics that he gave at a conference in Berlin on the 3rd Feb 2017 attended by over 250 scientists from around the world... | someuwin | |
09/2/2017 11:30 | Nef just SOHs brother,are you sure you own shares :)) ? or are you one of these posters who "keeps his feet on the ground" yawn yawn. | scotty1 | |
09/2/2017 11:25 | Lets hope P&G give approval for it to be announced in an RNS and not an interview. I guess probably not | onedayrodders | |
09/2/2017 11:23 | re 19754omg, jeeeezzzz, scotty you are not bringing up TW yet again, don't forget he is the creator of the soh's brother's/son/auntie | neftanikoff | |
09/2/2017 11:21 | Good observation - Someuwin. I don't think many doubted the veracity just the "imminent" delivery of the P&G news, which by all accounts is 12 months late, 16 months by Easter. I would have expected AR had a better understanding how these type of deals with MN playout before he gave TW the wink. | elrico | |
09/2/2017 11:17 | someuwin - i was thinking the same thing. I believe is was TW who confidently said the Asian MN was TATA and its proved correct. Whether this was orchestrated by Opti I don't know; however, for those that say TW talks boll*x, he was 100% this time. So, if it was also TW who started the P&G rumour, it has considerable credence. Still can't get my head around TATA news not being RNSed. With the news being dripped out via a minor news blog there has been zero impact on share price I would have thought that an agreement with a big MN such as Tata was market sensitive and so there was an obligation to RNS - but WTFDIK. | kipper1960 | |
09/2/2017 10:34 | Now that the TATA 'rumour' has been confirmed as true, it give more credence to the other 'rumour' that Procter & Gamble is the first multinational. After all they both came from the same source. | someuwin | |
09/2/2017 10:26 | Just means it was poorly packed - if it reduces cholesterol who gives a fig. | elrico | |
09/2/2017 10:26 | Nef, you seem to be eyeing other shares recent rises jealously. Do you not think they did the same a year or so ago when Opti went from 10p to £1? OXP crashed from 13p so it's only in early recovery mode. Do you really think it's a better bet than Opti as I don't. You do sound like someone who only bought in here around current levels for a quick buck ..if not, why so anxious to see immediate gains. I watched Opti for over a year before I felt comfortable enough in its progress to take my position a few months ago at 65p. | portrush | |
09/2/2017 10:24 | That cash position has been bugging me a little, but of course a large part of the answer lies here. "Under the terms of the agreement, OptiBiotix has increased its investment into SkinBiotix, using a Convertible Loan Agreement, with an investment of £400k which will provide funding to complete the development and human studies for the first product application, in addition to funding activities to support an Initial Public Offering ("IPO"). The loan will convert should SkinBiotix successfully complete and IPO." That's it. They've used toxic debt as possible funding for a possible IPO of SkinBiotix (although that's all gone very quiet I note). In other words the £400,000 investment will be debt on the balance sheet rather than a cash deduction, at this juncture anyway. It raises the following though. If the IPO doesn't go ahead then that £400,000 will come directly from cash resources. So £2.8m cash left which is getting close to my estimate. If the IPO does go ahead then what's the coupon on the debt? Normally quite high, and what will the conversion price be? Normally a hefty discount to the prevailing share price As ever there is very little detail about the terms. In summary, they owe £400,000 in debt. Looking forward to the results. | michaelmouse | |
09/2/2017 10:21 | Does the bouncing pill gives the same effect as uppers and downers? | asterix96 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions